A Randomized, Multi-Center Phase II Trail to Assess the Efficacy of 5-Azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML.

Trial Profile

A Randomized, Multi-Center Phase II Trail to Assess the Efficacy of 5-Azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Azacitidine (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms AML-AZA
  • Most Recent Events

    • 01 Dec 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.
    • 14 Apr 2012 Planned number of patients changed from 216 to 234 as reported by European Clinical Trials Database.
    • 14 Apr 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2008-004583-40).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top